Capricor reports Q4 2022 net loss $7.7M ($0.31/share); expands Nippon Shinyaku deal to Japan for $12M upfront

CAPRICOR THERAPEUTICS, INC.

Q4 2022 revenue $1.0M (Nippon Shinyaku upfront recognition) vs $0; net loss $7.7M vs $6.2M in Q4 2021.
Full-year 2022 net loss $29.0M ($1.18/share) vs $20.0M ($0.87/share); cash $41.4M as of Dec 31, 2022.
HOPE-3 Phase 3 trial for CAP-1002 in DMD >30% enrolled; interim analysis expected Q4 2023.
Japan partnership with Nippon Shinyaku: $12M upfront, up to $89M milestones, double-digit net revenue share.
Cash runway projected into Q4 2024, including $12M Japan upfront expected in Q1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.